Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Prior treatment

• Malignancy, except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ treated with curative intent, within the last 5 years.
• Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before check-in.
• Current or prior use of all herbal medicines, vitamins, and supplements consumed by the participant within the 30 days prior to check-in.
• Participant has received a dose of an investigational drug within the past 30 days or 5 half-lives, whichever is longer, prior to check-in.
• Have previously completed or withdrawn from this study or any other study investigating maridebart cafraglutide or have previously received maridebart cafraglutide.

Other illness

• History or evidence of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
• History or evidence of endocrine disorder that can cause obesity.
• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2.
• History or current signs or symptoms of cardiovascular disease.
• History of hypersensitivity, intolerance, or allergy to maridebart cafraglutide or related/similar compounds or its ingredients.

Lab values

• History of or active diabetes (regardless of type, except history of gestational diabetes), or hemoglobin A1c ≥ 6.5%.
• History of acute or chronic pancreatitis within 1 year prior to check-in, or elevation in serum lipase or amylase (\> 2 x upper limit of normal \[ULN\]) at screening or check-in, or fasting serum triglyceride level of \> 500 milligrams per deciliter (mg/dL) at screening.
• Estimated glomerular filtration rate ≤ 60 mL/min/1.73 m\^2 as calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (2021) at screening or check-in.
• Current use or prior use of any glucagon-like peptide-1 receptor (GLP-1R) agonist, glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist or antagonist within the past 3 months prior to check-in.

• Male or female participants, of any race, between 18 and 60 years of age (inclusive).
• Females must not be pregnant or lactating.
• Body mass index of ≥ 25.0 to \< 40.0 kilograms per square meter (kg/m\^2).
• Have a stable body weight within 3 months before screening.